Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Clarivate›
Analysis
AddedJul 9, 2026
UpdatedJul 9, 2026
Clarivate

Clarivate

Clarivate is a public analytics company providing subscription-based intellectual property, scientific, and academic information services.

HQ
Philadelphia, PA, US
Founded
2016
Loading
Overview
M & A
Analysis
Compare
Employees
News
Revenue Estimate
$2.6B

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths

Memo

Clarivate is a publicly listed information-services company (NYSE: CLVT) formed in 2016 from the Thomson Reuters Intellectual Property and Science carve-out. It sells curated data, analytics and workflow software across academia and government, life sciences and healthcare, and intellectual property, anchored by Web of Science, ProQuest, Ex Libris, Cortellis, Derwent and MarkMonitor.

Investment considerations center on the durability of its proprietary data franchises and high subscription renewal rates, balanced against leverage from its acquisition-led expansion, integration of large deals such as ProQuest, and structural change from AI-assisted discovery and open-access publishing that pressure legacy citation and content models.

Product Overview

Clarivate organizes its portfolio across three customer segments: Academia and Government, Life Sciences and Healthcare, and Intellectual Property. Within these it sells enriched data sets, predictive analytics, workflow software and expert services, anchored by products such as Web of Science, ProQuest and Ex Libris Alma for research and libraries, Cortellis for drug-development and regulatory intelligence, and Derwent, IPfolio and MarkMonitor for patent, trademark and brand protection.

Delivery is subscription-led: customers license curated proprietary data and software, often layered with analyst and consulting support from domain specialists. The same intelligence is packaged as recurring data feeds, SaaS workflow platforms and published reports such as Journal Citation Reports, Drugs to Watch and Top 100 Global Innovators.

Market Outlook

Demand for Clarivate's markets is supported by rising research output, the growth of global patent and trademark filings, and sustained life-sciences R&D investment, all of which increase the need for curated intelligence and workflow automation. Academic libraries, corporate R&D and IP teams, and pharmaceutical regulatory groups continue to consolidate on a small number of trusted data and software providers.

The business is also shaped by the shift toward AI-assisted discovery and open-access publishing, which pressures legacy citation and content models while creating opportunities to layer analytics and generative tools on top of proprietary data. Competitive intensity from Elsevier, Digital Science, EBSCO, Cengage, Questel and specialist life-sciences data vendors remains a structural feature of each segment.

Competitive Advantages

Clarivate's principal advantage is the depth and curation of its proprietary data. Web of Science and Journal Citation Reports, Derwent patent records, Cortellis drug and regulatory data, and ProQuest's aggregated content are long-standing, continuously maintained collections that are costly for a new entrant to replicate and are embedded in customer research, IP and regulatory workflows.

A second advantage is the pairing of that data with subject-matter expertise and switching costs. The company employs hundreds of PhD-level analysts and its tools sit inside daily library, patent, clinical and brand-protection processes, so customers integrate the data into citations, filings and decisions in ways that raise the cost of displacement.